Spruce Biosciences Inc (SPRB)
Spruce Biosciences, Inc. is a biopharmaceutical company developing therapies for neurological disorders and other serious rare diseases. Its pipeline includes TA-ERT, an enzyme replacement therapy candidate for Sanfilippo Syndrome Type B, as well as Tildacerfont, which is being studied for a severe mental disorder marked by depressed mood and related cognitive, emotional, and physical symptoms. The company is also advancing SPR202 for Congenital Adrenal Hyperplasia, a chronic rare disease with no cure. Spruce Biosciences has a license agreement with Eli Lilly and Company covering research, development, and commercialization of certain pharmaceutical compounds, and a collaboration with Kaken Pharmaceutical Co. Ltd. focused on Tildacerfont for CAH in Japan. Incorporated in 2014, the company is headquartered in South San Francisco, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SPRB
|
$55.20
|
10.4% Upside
|
Fair
|
$148
|
196.1% Upside
|
Bargain
|
Fair
|
0.0%
|
November 16, 2026
|
1.8x
|
143.7 M
|
65.711 M
|
4.7%
|
70.2%
|
0.3
|
83.3%
|
